EGFR and non-small cell lung carcinoma: The most common adverse events of administration of EGFR-TKIs in advanced NSCLC are skin toxicity, gastrointestinal toxicity, pulmonary toxicity, hepatic toxicity, and ocular toxicity [26,47,48,49].